Among those, peroxisome proliferator-activated receptor (PPAR) agonists have sparked major interest as therapeutic agents for MASH, given the pleiotropic roles of the three PPAR isotypes (α, β/δ, γ) in the regulation of energy metabolism, fibrosis, and inflammation, but also their role in endothelial cells and their impact on IHVR in models of portal hypertension.[30], [31], [32] However, the effect of PPAR agonists on the hepatic vasculature in early MASLD and MASH has not been investigated. The gene discussed is PPARA; the disease is portal hypertension.